| Time | Session |
|---|---|
|
14:00
15:40
|
(Separate pre-registration required)
Room F1+2+3
|
|
15:40
16:10
|
Refreshment Break
|
|
16:10
18:25
|
(Separate pre-registration required)
Room F1+2+3
|
|
18:30
20:00
|
Early Career Networking Reception
Main Foyer
Room F1+2+3
|
| Time | Session | |||||
|---|---|---|---|---|---|---|
|
08:30
10:00
|
(Separate pre-registration required)
Room F1+2+3
|
|||||
|
09:00
14:00
|
Women in Leadership
(Separate pre-registration required)
Off-site Venue
|
|||||
|
10:00
12:00
|
Room F6+7+8
|
|||||
|
10:30
12:00
|
This session focuses on career progression, offering participants the opportunity to engage directly with the four Award Winners in an informal, highly interactive format. Each expert will begin with a 7 minute personal introduction, sharing their career path, key decisions, and lessons learned. A moderator may pose follow-up questions to deepen the discussion and draw out practical insights. The floor is then opened to the audience for an open Q&A, encouraging participants to ask questions in an “Ask Me Anything”–style exchange. Designed as a fully interactive session, this format features no slides and no screen, prioritizing conversation, accessibility, and direct engagement between Award Winners and participants.
Career Development Area
|
(Separate pre-registration required)
Room F1+2+3
|
||||
|
12:00
14:00
|
Lunch Break / Exhibition
Poster and Exhibition Hall
Room P1+2+3
|
|||||
|
12:00
20:00
|
Exhibition
Poster and Exhibition Hall
|
|||||
|
12:15
13:00
|
This symposium addresses the critical shift toward multi-resolution, multi-modal approaches that enable the precise deconstruction of the tumor ecosystem to achieve a system-level understanding of cancer progression. The session will begin with an overview of emerging innovations expanding the resolution and scope of cancer research, followed by expert‑led research demonstrating the utility of spatial transcriptomics for tumor microenvironment analysis and high‑plex functional proteomics for uncovering protein‑level drivers of cancer biology. Building on these applications and using Illumina Connected Multiomics (ICM) as a framework, an R&D‑led technical deep dive will examine analytical considerations for single‑omic and integrated multiomic analysis across single‑cell, spatial, transcriptomic, proteomic, genomic, and epigenomic data. Through practical examples, this session will demonstrate how AI guided workflows, structured data exploration, and intuitive visualisation make advanced multiomic analysis accessible, enabling researchers to confidently apply multiomic approaches in their own studies. Join us to explore how these multidimensional results, powered by high‑fidelity sequencing and accessible data analytics are providing the clarity needed to decipher the functional drivers of cancer and advance the next wave of precision oncology.
Room F1+2+3
|
Biology is complex, and the mechanisms that drive biological systems are challenging to decipher. Examining any single layer of biology can provide a valuable perspective, but it reveals only part of the picture. Bruker Spatial Biology delivers best-in-class solutions designed to work together as a cohesive ecosystem. By providing high fidelity resolution and information depth across layers of biological complexity, Bruker Spatial Biology enables insights that cannot be achieved by single layer approaches, accelerating discovery through translational cancer research. Prof. Pagani will exemplify how his laboratory is using CosMx Same-Cell Multiomics to determine metastatic cell states in colorectal cancer.
Room F9+10
|
||||
|
12:30
13:45
|
(open to EACR Early Career & Student Members, pre-registration required)
Career Development Area
|
|||||
|
13:15
14:00
|
This symposium addresses the critical shift toward multi-resolution, multi-modal approaches that enable the precise deconstruction of the tumor ecosystem to achieve a system-level understanding of cancer progression. The session will begin with an overview of emerging innovations expanding the resolution and scope of cancer research, followed by expert‑led research demonstrating the utility of spatial transcriptomics for tumor microenvironment analysis and high‑plex functional proteomics for uncovering protein‑level drivers of cancer biology. Building on these applications and using Illumina Connected Multiomics (ICM) as a framework, an R&D‑led technical deep dive will examine analytical considerations for single‑omic and integrated multiomic analysis across single‑cell, spatial, transcriptomic, proteomic, genomic, and epigenomic data. Through practical examples, this session will demonstrate how AI guided workflows, structured data exploration, and intuitive visualisation make advanced multiomic analysis accessible, enabling researchers to confidently apply multiomic approaches in their own studies. Join us to explore how these multidimensional results, powered by high‑fidelity sequencing and accessible data analytics are providing the clarity needed to decipher the functional drivers of cancer and advance the next wave of precision oncology.
Room F1+2+3
|
QIAGEN GmbH Industry Symposium
Room F9+10
|
||||
|
14:00
15:15
|
Room F1+2+3
|
Room F6+7+8
|
Room P1+2+3
|
|||
|
15:15
15:45
|
Coffee Break / Exhibition
Poster and Exhibition Hall
Room P1+2+3
|
Meet and Greet EACR Ambassador and Solo Travellers
(at the Networking Lounge)
Room P1+2+3
|
||||
|
15:45
18:20
|
Room P1+2+3
|
|||||
|
18:20
18:35
|
EACR General Assembly and Awards Ceremony (EACR Members only)
P1+2+3
Room P1+2+3
|
Welcome Reception (Exhibition Area)
Poster and Exhibition Hall
Room P1+2+3
|
||||
|
18:45
19:00
|
CancerTools.org Industry Spotlight Session
Spotlight Theatre
|
|||||
|
19:15
19:30
|
Element Biosciences Industry Spotlight Session
Spotlight Theatre
|
|||||
| Time | Session | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
08:30
09:15
|
This interactive session focuses on grant funding, offering participants direct access to funders and grantmakers. Each expert will give a 5-minute introduction, outlining their role, funding priorities, and perspectives on the grant-making process. A moderator will pose follow-up questions to deepen the discussion and highlight practical insights. The session then opens to the audience for an open “Ask Me Anything” Q&A, encouraging candid questions and active participation. Designed as a fully interactive format, the session includes no slides or screens, prioritizing conversation and direct engagement.
Career Development Area
|
Join Atlas Antibodies for an exploration into the evolution of spatial proteomics, rooted in the 20-year legacy of the Human Protein Atlas (HPA). This symposium demonstrates how the rigorously validated primary antibodies that built the HPA are now driving advanced functional discovery in cancer research. The session will cover two key technical workflows: Atlasplex, a streamlined solution for targeted 3-5 marker multiplexing, and Molboolean, an innovative technology using rolling circle amplification to detect protein-protein interactions in situ. Attendees will learn how to bridge the gap between static tissue maps and dynamic functional insights, utilizing high-certainty reagents to characterize cellular "neighborhoods" and molecular interactions. Whether you are looking to optimize your multiplexing efficiency or investigate protein-protein complexes, this session provides a practical roadmap for turning routine IHC into high-dimensional data.
Room F1+2+3
|
Oxford Nanopore Technologies Industry Symposium
Room F6+7+8
|
|||||||||
|
09:20
10:55
|
Room F1+2+3
|
Room F6+7+8
|
Room P1+2+3
|
|||||||||
|
10:30
20:00
|
Poster Session Tuesday (Poster Viewing)
Poster and Exhibition Hall
|
|||||||||||
|
10:30
19:00
|
Exhibition
Poster and Exhibition Hall
Poster and Exhibition Hall
|
|||||||||||
|
10:55
11:35
|
Coffee Break / Exhibition / Industry Spotlight
Exhibition and Poster Hall
Room P1+2+3
|
|||||||||||
|
11:10
11:25
|
Spotlight Theatre
|
|||||||||||
|
11:35
13:10
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
|
||||||||
|
13:15
15:15
|
Lunch Break / Exhibition / Poster Viewing
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
13:30
14:15
|
Bio-Rad Laboratories Industry Symposium
Room F1+2+3
|
This session, sponsored by biomodal, will introduce the duet cfDNA solutions as complete integrated genetic and epigenetic workflows and software. The duet cfDNA solutions unlock the broadest spectrum of biomarkers, with market leading accuracy, from a single low input cfDNA sample, enabling ultra-low LoD for the detection of ctDNA. Talks will demonstrate how, in a liquid biopsy setting, 6-base data detects cancers earlier than other methylation sequencing approaches across multiple cohorts. Additional data will show how 6-base data enables a better understanding biological mechanisms of prostate cancer treatment response than existing liquid biopsy approaches.
Room F6+7+8
|
Dr. Wiesner will highlight how Advanced Cell Diagnostics and Lunaphore, Bio-Techne brands, are transforming the future of oncology research and precision medicine with spatial biology tools. Dr. Karen, from the Weizmann Institute of Science, will talk about how modern lung cancer treatment depends on multiple biomarkers, but current diagnostic workflows exhaust small biopsies and slow down life-saving therapy decisions. Her team developed a multiplexed imaging approach that reads dozens of markers from one tissue section, enabling comprehensive diagnosis while conserving tissue and shortening turnaround time.
Room F9+10
|
|||||||||
|
13:45
15:00
|
Career Development Session 1A
(open to EACR Early Career & Student Members, pre-registration required)
Career Development Area
|
|||||||||||
|
14:30
15:15
|
Discover how 3D chromatin organization acts as a master regulator of leukemia biology, learn cutting-edge approaches to profile spatial genome architecture in cancer, and understand how linking chromatin structure to gene expression networks can identify new precision medicine strategies for improving patient outcomes. • Learn how 3D chromatin conformation capture can distinguish leukemia subtypes and pinpoint their cells of origin by mapping lineage-defining regulatory hubs. • Explore how 3D genome profiling uncovers intra‑tumor heterogeneity in T‑ALL, providing new biomarkers to anticipate and monitor therapy response. • See how chromatin interaction matrices expose structural variants and enhancer hijacking events that drive oncogene activation and leukemic transformation.
Room F1+2+3
|
Over three decades, 3DHISTECH has advanced digital pathology through comprehensive 2D imaging solutions spanning the entire diagnostic workflow. Yet tissue is inherently three dimensional. The Pannoramic X micro CT introduces a breakthrough in 3D digital pathology by enabling ultra-high resolution imaging of intact FFPE blocks, macroblocks, and large specimens without sectioning or staining. Using soft X ray virtual slicing and staining, it preserves tissue integrity while revealing unprecedented morphological and biomarker detail. Integrated with advanced visualization and AI driven analysis, the system enhances tumor assessment, cancer staging, and research applications. The future of pathology is volumetric—unlocking deeper insight through true 3D tissue exploration.
Room F6+7+8
|
Room F9+10
|
|||||||||
|
15:20
16:55
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
|
||||||||
|
16:55
17:30
|
Coffee Break / Exhibition / Industry Spotlight
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
17:10
17:25
|
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic disease associated with chronic wounds and a high risk of aggressive cutaneous squamous cell carcinoma (cSCC), for which effective treatments are lacking. This study investigates a multi-omics-driven drug repurposing strategy to identify new therapeutic options. Integrated analysis of molecular data revealed dysregulated pathways in RDEB-associated cSCC and identified statins as potential anti-tumor agents. To validate this, statins were tested in vitro using EB-derived cancer cell models. Functional assays assessing cell viability and cytotoxicity were performed using automated plate-based detection, including the Tecan Spark® Cyto, enabling reproducible and quantitative evaluation of cellular responses. Preliminary results showed reduced cancer cell viability, supporting a potential anti-tumor effect. Ongoing in vivo studies using xenograft models aim to determine whether these findings translate into tumor growth inhibition. This work highlights the potential of combining multi-omics analysis with automated functional validation to accelerate drug repurposing for rare and life-threatening diseases.
Spotlight Theatre
|
|||||||||||
|
17:30
18:15
|
Room P1+2+3
|
|||||||||||
|
18:15
18:40
|
Posters in the Spotlight Tuesday
Spotlight Theatre
Room P1+2+3
|
|||||||||||
|
18:40
20:00
|
Poster Discussion Session TUESDAY (at Poster Area)
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
| Time | Session | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
08:30
09:15
|
This interactive session explores collaboration between industry and academia, offering practical perspectives from industry experts. Each expert will deliver a 5-minute introduction, sharing their experience, role, and insights into working across sectors. A moderator will guide the discussion with follow-up questions to deepen the conversation and surface actionable takeaways. The session then opens to the audience for an open “Ask Me Anything” Q&A, encouraging questions and active participation. Designed as a fully interactive format, the session features no slides or screens, prioritizing dialogue and direct engagement.
Career Development Area
|
sponsored Industry Symposium
Room F1+2+3
|
TP53 mutations are common in AML, often as “multi-hit” types linked to complex karyotypes. Using single-cell DNA sequencing and phenotypic analysis, we examined the zygosity and clonal architecture of TP53m AML. Among eight patients, “multi-hit” TP53 anomalies appeared in blast cells but not in mature lymphoid populations. Minor TP53m heterozygous clones persisted in mature cells and at remission, with dominant “multi-hit” clones resurfacing at relapse. The combined scDNAseq and CITEseq approach highlights distinct mutation patterns, aiding therapy guidance by distinguishing pathological multi-hit mutations from clonal haematopoiesis at remission.
Room F6+7+8
|
|||||||||
|
09:20
10:55
|
Room F1+2+3
|
Room F6+7+8
|
Room P1+2+3
|
|||||||||
|
10:30
20:00
|
Poster Session Wednesday (Poster Viewing)
Poster and Exhibition Hall
|
|||||||||||
|
10:30
19:00
|
Exhibition
Poster and Exhibition Hall
|
|||||||||||
|
10:55
11:35
|
Coffee Break / Exhibition / Industry Spotlight
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
11:10
11:25
|
Cellecta, Inc. Industry Spotlight Session
Spotlight Theatre
|
|||||||||||
|
11:35
13:10
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
|
||||||||
|
13:15
15:15
|
Lunch Break / Exhibition / Poster Viewing
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
13:30
14:15
|
Understanding cancer biology through a single molecular lens often leaves critical mechanisms unresolved. Increasingly, researchers are combining complementary molecular layers to build a more comprehensive view of disease—connecting genetic, epigenetic, proteomic, and spatial signals to better understand tumor development, heterogeneity, and progression. This symposium brings together scientists applying integrated multiomic approaches to address complex biological questions in cancer research. By featuring perspectives from researchers at different stages of their scientific careers, the session highlights how connecting diverse molecular signals into a unified analytical view is driving biological discovery and translational investigation. Together, these perspectives illustrate how examining cancer biology from multiple, complementary molecular angles supports a more comprehensive understanding of cancer biology.
Room F1+2+3
|
F.Hoffmann - La Roche Industry Symposium
Room F6+7+8
|
FFPE is the most abundant clinical sample type used in cancer research. However, extracting high-quality genomic, transcriptomic, and proteomic data from FFPE remains a major challenge. This symposium explores robust and reliable sample preparation workflows that transform FFPE from a difficult specimen into a powerful resource for multi-Omics analysis. Experts will highlight AFA enabled workflows that maximize analyte recovery, preserve molecular integrity, and deliver confident results for DNA, RNA, and proteins. Discover how integrated, automation ready workflows can provide deeper insights from FFPE, thereby accelerating biomarker discovery, translational research, and precision oncology.
Room F9+10
|
|||||||||
|
13:45
15:00
|
Career Development Session 2A
(open to EACR Early Career & Student Members, pre-registration required)
Career Development Area
|
|||||||||||
|
14:30
15:15
|
Spatial biology enables detailed analysis of molecular processes within native tissue architecture. Using MACSima® Imaging Cycling Staining (MICS), hundreds of proteins and dozens of RNA markers can be detected on the same section, generating high dimensional datasets that enhance cellular characterization and improve therapeutic target solutions. After an introduction into Miltenyi Biotec's innovative spatial biology and imaging solutions, we will demonstrate how B cells play a pivotal role in shaping the TME and tertiary lymphoid structures (TLS). The functions of specific B cell subsets in cancer pathogenesis remain unclear. Using a tissue-centric single-cell RNA-sequencing pipeline, flow cytometry, and high-plex spatial biology MACSima platform, we identify CD27⁻IgD⁻CD21⁺CD11c⁻ double negative 1 (DN1) B cells as a regulatory population enriched in RCC tumours and associated with worse prognosis. These cells localize within immature tertiary lymphoid structures near IL-10⁺ and TGFβ⁺ CD8⁺ T cells. TLR signalling drives their differentiation, and DN1 B cells suppress CD8⁺ T cell cytotoxicity partially via IL-10 and TGFβ. Our findings reveal a novel immune evasion mechanism with potential diagnostic and therapeutic relevance.
Room F1+2+3
|
sponsored Industry Symposium
Room F6+7+8
|
Olink, part of Thermo Fisher Scientific Industry Symposium: Advancing Cancer Research Beyond the Genome with Plasma Proteomics
Proteomics is reshaping cancer research by providing functional insights that extend beyond the genome. This session highlights how high-throughput plasma protein profiling supports biomarker discovery, patient stratification, and a deeper understanding of cancer biology. Our speakers will present applications spanning early detection, immuno-oncology, and translational research, showcasing the expanding role of proteomics across the cancer research continuum. Together, these examples underline the potential of scalable proteomic approaches to generate more precise, biologically meaningful, and clinically relevant insights in oncology.
Room F9+10
|
|||||||||
|
15:20
16:55
|
Room F1+2+3
|
Room F6+7+8
|
Room F9+10
|
Room P1+2+3
|
||||||||
|
16:55
17:30
|
Coffee Break / Exhibition / Industry Spotlight
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
|
17:10
17:25
|
LGC Industry Spotlight Session
Spotlight Theatre
|
|||||||||||
|
17:30
18:15
|
Room P1+2+3
|
|||||||||||
|
18:15
18:40
|
Posters in the Spotlight - Wednesday
Spotlight Theatre
Room P1+2+3
|
|||||||||||
|
18:40
20:00
|
Poster Discussion Session WEDNESDAY (at Poster Area)
Poster and Exhibition Hall
Room P1+2+3
|
|||||||||||
| Time | Session |
|---|---|
|
09:00
09:45
|
Room P1+2+3
|
|
09:45
11:00
|
Room P1+2+3
|
|
11:00
11:20
|
Coffee Break
Main Foyer
Room P1+2+3
|
|
11:20
12:05
|
Room P1+2+3
|
|
12:05
13:00
|
Room P1+2+3
|